Across TCGA pan-cancer cohorts, HSH2D RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of HSH2D’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where HSH2D RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HSH2D is over-expressed in tumor, although a few such as LUSC and KICH show the opposite, repressed pattern.
LUAD, STAD, and LUSC are the cancer types where HSH2D tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSH2D RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.